Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.
Ascierto PA, Dummer R, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Robert C, Flaherty KT. Ascierto PA, et al. Among authors: dutriaux c. J Clin Oncol. 2023 Oct 10;41(29):4621-4631. doi: 10.1200/JCO.22.02322. Epub 2023 Jul 28. J Clin Oncol. 2023. PMID: 37506329 Free PMC article. Clinical Trial.
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.
Leroy V, Gerard E, Dutriaux C, Prey S, Gey A, Mertens C, Beylot-Barry M, Pham-Ledard A. Leroy V, et al. Among authors: dutriaux c. Cancer Immunol Immunother. 2019 Apr;68(4):545-551. doi: 10.1007/s00262-019-02298-9. Epub 2019 Jan 19. Cancer Immunol Immunother. 2019. PMID: 30661086 Free PMC article.
Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P. Ilie M, et al. Among authors: dutriaux c. J Am Acad Dermatol. 2015 May;72(5):786-93. doi: 10.1016/j.jaad.2015.01.012. Epub 2015 Feb 7. J Am Acad Dermatol. 2015. PMID: 25659223
Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma.
Barailler H, Salomon G, Dutriaux C, Prey S, Gérard E, Dousset L, Mertens C, Beylot-Barry M, Meyer N, Pham-Ledard A. Barailler H, et al. Among authors: dutriaux c. J Geriatr Oncol. 2020 Nov;11(8):1340-1343. doi: 10.1016/j.jgo.2020.03.003. Epub 2020 Mar 18. J Geriatr Oncol. 2020. PMID: 32199777 No abstract available.
[Impact on quality of life and autonomy of patients aged over 75 years treated with anti-PD-1 for metastatic melanoma: A single-centre prospective study].
Barailler H, Dousset L, Mertens C, Maurel A, Gérard E, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Barailler H, et al. Among authors: dutriaux c. Ann Dermatol Venereol. 2020 Nov;147(11):713-720. doi: 10.1016/j.annder.2020.07.012. Epub 2020 Sep 28. Ann Dermatol Venereol. 2020. PMID: 33004209 French.
114 results